

## Increased oscillation rate may improve morcellation efficiency in HoLEP

Cameron McClaine, Thomas M. Shelton, Austen Slade, Andrew Adeola, Marcelino E. Rivera

Department of Urology, Indiana University School of Medicine, Indianapolis, IN, United States

Cite as: McClaine CA, Shelton TM, Slade AD, et al. Increased oscillation rate may improve morcellation efficiency in HoLEP. *Can Urol Assoc J* 2025;19(3):E80-4. <http://dx.doi.org/10.5489/cuaj.8873>

Published online November 4, 2024

### ABSTRACT

**INTRODUCTION:** Tissue morcellation has become increasingly efficient, yet remains a rate-limiting step in holmium enucleation of the prostate (HoLEP). Limited data exists on how the rate of oscillation by the morcellator blades affects morcellation efficiency (ME).

**METHODS:** We undertook a retrospective review of HoLEP procedures performed by two surgeons from July 1, 2019, to August 25, 2022. All morcellation was performed with the Wolf Piranha device and enucleation was performed with Moses 2.0 technology. Surgeon 1 routinely uses 1500 oscillations/min (low rate [LR]) and surgeon 2 uses a rate of 6000 oscillations/min (high rate [HR]). These rates were confirmed upon electronic medical record review of each case. The primary endpoint was ME (g/minute). Secondary endpoints included enucleation efficiency (EE), mean tissue specimen weight, and preoperative prostate volume.

**RESULTS:** A total of 894 HoLEPs were analyzed, 592 by surgeon 1 and 302 by surgeon 2. Surgeon 1 had larger preoperative prostate volumes (126 vs. 101,  $p < 0.001$ ) and specimen tissue weights (86.0 vs. 61.1,  $p < 0.001$ ). EE was higher in the LR group (1.67 vs. 1.33 g/min,  $p < 0.001$ ). Morcellation time was longer in the LR group (11.3 vs. 6.09 min,  $p < 0.001$ ) and ME was lower in the LR group (9.26 vs. 12.1 g/min,  $p < 0.001$ ). The difference in ME was inversely proportional to specimen weight.

**CONCLUSIONS:** Increased oscillation rate during morcellation may lead to decrease in morcellation time and increased ME during prostate enucleation. The primary limitation of this paper is the inclusion of only two surgeons. Future studies will serve to evaluate this finding across a larger number of institutions, and evaluate ways to increase ME in large prostate cohorts.

### INTRODUCTION

Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical treatment for patients with symptomatic benign prostatic hyperplasia (BPH).<sup>1</sup> The procedure provides advantages over transurethral resection of prostate (TURP) in prostates above 80 g and proves to be the single most cost-effective surgical treatment of BPH at five years postoperatively.<sup>2,3</sup> As such, HoLEP offers an appealing option to patients who desire surgical management of BPH with successful and durable outcomes.

HoLEP has further demonstrated superiority to TURP in terms of postoperative catheterization time and hospitalization duration;<sup>4</sup> however, when compared to TURP, HoLEP operative times are 16 minutes longer in preoperative size-matched prostates.<sup>5</sup> This increase in time can translate into increased operative costs. A study of over 300 facilities by Childers and colleagues estimated the average operating room (OR) costs to be 36–37 dollars/minute for acute care hospitals in fiscal year 2014.<sup>6</sup> Furthermore, a tertiary care center for urolithiasis estimated their OR costs to be anywhere from 64–115 dollars/minute.<sup>7</sup> With these significant costs in mind, any incremental changes in the operative flow of HoLEP procedures would be a welcomed value enhancement.

HoLEP can be divided into enucleation and morcellation phases. Significant efforts have been employed to improve enucleation time since the advent of HoLEP. Improvement in laser technology

## KEY MESSAGES

- Tissue morcellation was more efficient when using a higher rate of oscillation.
- The difference in morcellation efficiency was inversely proportional to specimen weight.
- Our subgroup analysis revealed a difference in efficiency up to a resected tissue weight of 150 g.
- This study helps expand the possibilities of one aspect of HoLEP and refine mechanical morcellation techniques.

with the advent of the MOSES™ pulsed modulation has enhanced operative efficiency.<sup>8</sup> Additionally, evolving operative technique with en bloc resection has sought to decrease enucleation times;<sup>9</sup> however, different enucleation power settings have been shown to have no significant effect on intra- or postoperative variables like operative efficiency, bleeding rates, and other complication rates.<sup>10</sup> While much focus has been placed on enucleation, the literature on morcellation efficiency (ME) has been sparse.

Following enucleation of the prostatic adenoma, morcellation is performed to remove the benign tissue from the bladder and urethral space.<sup>11</sup> Currently, the safest and most efficient morcellator device is the Wolf Piranha.<sup>12</sup> In practice, morcellation oscillation rates can range from 0–6000 oscillations per minutes. Currently, there is minimal guidance on ideal morcellator settings to maximize efficiency of morcellation. Oscillating techniques have already been shown to be superior to reciprocating blades in the mechanical morcellation of enucleated tissue.<sup>13</sup> Previous studies have demonstrated optimal morcellator device design while characterizing the efficiencies at base oscillation rates and size-dependent factors affecting morcellation. The current manufacturer's recommendation for the Piranha (Wolf) morcellators is up to 1500 rpm;<sup>14,15</sup> however, no data exists on the limits of morcellator oscillation speed and clinical safety profiles at high rates.

This study aims to assess how operative times differ across various morcellation settings, to evaluate the upper and lower limits that optimize performance, and to determine the range of ideal morcellator settings that maximize both safety and efficiency in HoLEP

procedures. Ideally, this inquiry serves to decrease the costs associated with HoLEP procedures and would serve the interests of both urologic providers and BPH patient cohorts alike.

## METHODS

After obtaining institutional board review approval, we carried out a retrospective review of HoLEP procedures by two surgeons from July 1, 2019, to August 25, 2022. This timeframe was chosen to represent the most modern cohort available and ensure consistency in equipment. All morcellation was performed with the Wolf Piranha device and disposable morcellation blades. For enucleation, MOSES 1.0 and above technology was used at 1–2 J and 20–60 Hz. MOSES 2.0 was used from 2020 onward. Sheath size was 28 French in both groups.

All surgeons were fellowship-trained in endourology and surpassed the learning curve by the beginning of this study. From our existing dataset of 2482 patients, we identified 1083 patients for analysis based on available oscillation rate data; 189 were excluded due to insufficient morcellation/enucleation data or insufficient documentation, leaving a total of 894 patients (Figure 1). Surgeon 1 routinely uses 1500 oscillations/min (low rate), and surgeon 2 uses a higher rate of oscillations/min, starting at 6000 and transitioning to 4000 and 2000 for denser tissue.

The primary endpoint was ME (g/min). Secondary endpoints included enucleation efficiency (g/min), mean tissue specimen weight (g), and preoperative prostate volume (g). Data was collected from multiple perioperative electronic medical record (EMR) documents, including intraoperative notes and immediate postoperative notes. Morcellation time started explicitly when the morcellator engaged the enucleated prostatic tissue. All sensitive patient information was extracted from Cerner (Cerner Corporation, Kansas City, MO, U.S.) and stored on institutionally approved software programs. Enucleation efficiency was calculated as enucleation time divided by specimen weight in grams for each subject. The tissues weights were reported on the same immediate postoperative note. The preoperative prostate volumes were extracted from H&P notes from the surgeon performing the respective patient's HoLEP. All continuous variables were presented as mean values with standard deviations. They were then divided into low rate (LR) and high rate (HR) populations and compared using two-tailed T-tests, assuming equal variance.

The data was also subgrouped into small, medium, and large resected tissue weights (<80 g, 80–150 g,




Figure 1. Flowchart depicting selection process for patients.

	Low rate (n=592)	High rate (n=302)	p
Resected tissue weight	85.98 (64.65)	61.08 (51.52)	<0.0001
Morcellation time	11.28 (10.96)	6.09 (6.81)	<0.0001
Morcellation efficiency	9.26 (4.50)	12.13 (5.60)	<0.0001
Enucleation time	51.80 (23.68)	43.02 (18.07)	<0.0001
Enucleation efficiency	1.67 (1.04)	1.33 (0.87)	<0.0001

and >150 g) to delineate any differences in the different patient cohorts. Statistics were performed with Microsoft excel (version 16.74) and graphs were organized using GraphPad-Prism (Version 9).

**RESULTS**

A total of 894 HoLEPs were analyzed, 592 by surgeon 1 and 302 by surgeon 2. Between the LR and HR morcellation groups, there was a difference in preoperative prostate volume (125.67±65.6 vs. 100.81±57.3 g, p<0.001). Enucleation efficiency was higher in the LR group (1.67±1.04 vs. 1.33±0.87 g/min, p<0.001). Morcellation time was longer in the LR group

(11.28±10.96 vs. 6.09±6.81 min, p<0.001) and ME was lower in the LR group (9.26±4.50 vs. 12.13±5.60 g/min; p<0.001) (Table 1). The difference in ME was inversely proportional to specimen weight (Figure 2).

When the data was subgrouped by intraoperative resected tissue weight (≤150 g and >150 g), there was a significant difference below 150 g (9.36±4.71 vs. 12.30±5.68, p<0.001) in ME, yet no significant difference in the large tissue group (8.66±2.71 vs. 9.36±2.78, p=0.34) (Figure 3). The data was further subgrouped to <80 g, 80–150 g, and >150 g. There was a significant difference below 80 g (9.63±5.37 vs. 12.81±6.19 g/min, p<0.001) and between 80–150 g (8.90 ±3.25 vs. 10.60±2.90, p<0.001); however, no significant difference remained above 150 g (8.66±2.71 vs. 9.36±2.78, p=0.34).

**DISCUSSION**

The difference in preoperative prostate volumes was significantly different across the two morcellation groups (126 vs. 101 mL). Previous studies have shown ME worsens >80 g, which would affect both groups in our current study.<sup>16</sup> In contrast to previous studies of LR morcellation (6.7–8.6 g/min),<sup>13,14</sup> our LR group had a mean ME of 9.26 g/min. Morcellation of 9.26 g/min exceeded efficiency elsewhere, despite the relatively large prostate volumes. This finding may be due to the relatively larger case density (CD) of HoLEP at 38.67 average cases per month. If physicians on the learning curve perform superiorly above a monthly CD of three, then surgeons 1 and 2 should intuitively have baseline efficiencies above average.<sup>17</sup>

A point of contention lies in the difference between the two surgeons' resected tissue weight. Assmus et al identified an equation (y=-0.3338x+10.012) to calculate expected ME based on resected weight from surgeon 1 and another provider.<sup>18</sup> X is equivalent to resected tissue weight in intervals of 25 g. The predicted difference in ME should only be around 0.34 g/min (9.20–8.86 g/minute) based on findings of previous literature. This lies in contrast to the difference of 2.87 g/min in our current study. Therefore, the difference in prostate size and resected weight can only partially explain the variations in efficiency, both for morcellation and enucleation. One of the main findings of our study is this difference in efficiency of multiple grams/minute between morcellator speeds. The cost of OR time in tertiary urologic centers can be upwards of 64–115 dollars per minute; therefore, even a difference of a few minutes per case can accumulate significant savings over the course of a month, year, or career of surgeons.

The data was further subgrouped into groups based on resected tissue weight to evaluate if there was an identifiable difference between small (<80 g), medium (80–150 g), and large (>150 g). There was a significant difference for LR and HR groups <80 g (9.63 vs. 12.81 g/min,  $p<0.001$ ) and between 80–150 g (8.90 vs. 10.60 g/min,  $p<0.001$ ); however, this did not remain the same >150 g (8.66 vs. 9.36 g/min,  $p=0.339$ ). There was still a substancial difference in the raw data that will need a higher-powered sample size to fully identify any differences. Our n-values for the above prostate groups were only 80 for LR and 17 for the HR group. A future study could explore the use of varying morcellation speeds in the large tissue group beyond our single-center study design. HoLEP has proven to be effective and clinically safe in subgroups of men with “massive” prostates >150 g, yet the operative efficiency of these subgroups has been sparingly explored.<sup>19</sup>

The inclusion of nearly 900 patients is by far the most by any paper specifically looking into morcellation speeds.<sup>14</sup>

### Limitations

The primary limitation of this paper is the inclusion of only two surgeons in a retrospective, single-center study. Future studies would include patent-matched, randomized control trials that would explore the differences in perioperative times and patient outcomes. Additionally, there are aspects of each patient's prostate that allow for inter-patient variability, as well as inter-provider differences. To account for one of these common factors, the EMR details were meticulously combed to exclude any cases of reported dense prostatic tissue (“beach ball” prostates) that would have positively skewed the data in a non-representative manner. In cases with beach ball prostates, the morcellation time averaged around 51.4 minutes.

This study did not control for history of urinary tract infections and/or intermittent catheterization, which can negatively affect morcellation times as well.<sup>20</sup> Other factors include where providers lie on the learning curve, trainee involvement, meticulousness of hemostasis, resectoscope type, prostate-specific antigen density, and prostatic calcifications.<sup>21</sup> These demographic factors did not necessarily affect our data; however, future multicenter studies may have to control for a wide variety of morcellation brands, resectoscope types, and other patient demographics.<sup>22</sup>

A common concern with HoLEP and increased oscillation rates is the potential for damage to the bladder wall.<sup>23</sup> An acceptable endoscopic view, continuous




Figure 2. Morcellation efficiency categorized by specimen weight between low-rate (LR) and high-rate (HR) groups.




Figure 3. Morcellation efficiency subdivided by specimen weight. \*Significant ( $p<0.05$ ).

irrigation, and well-trained OR staff are all mainstay ways to ensure safe morcellation;<sup>24</sup> however, there have been reports in the literature of bladder neck injury and associated bleeding.<sup>25</sup> This can be managed by morcellating in proper right to left motions with careful advancement in addition to the safeguards.<sup>26</sup> We did not observe a single bladder injury with the LR or HR morcellator settings. This study serves to solidify the efficiency of HR morcellation, yet further work needs to be done to establish this approach as potential HoLEP standard of care. The respective results for operative pathology outcomes were not collected for this study.

Assigning surgeons to each respective morcellation setting groups adds limitations. All cases were truly morcellated at either 6000 or 1500 rpms, with the exception of particularly difficult prostate tissue, where surgeon 2 was forced to transiently adjust with slower oscillating speeds (i.e., 4000 and below). This naturally adds a limitation, as there is no way to adjust for these changes under the current methodologic design.

One final limitation pertains to how preoperative prostate volumes were estimated. In a small minority of cases, preoperative prostate volumes were estimated based on digital rectal exam. These values have been shown to be commonly underestimated above transrectal ultrasound-calculated volumes of 30 g.<sup>27</sup> Preoperative magnetic resonance imaging could further evaluate lobar anatomy, phenotypic classification systems of BPH, and inform treatment if patients do not follow through with surgery.<sup>28</sup>

### CONCLUSIONS

This paper provides preliminary evidence into the usage of higher oscillation rates when morcellating prostate tissue. The existing literature has proven the safety and efficacy of low oscillation rates; however, this study explores an expanded range of oscillation rates and how they impact operative efficiency. Increased oscillation rates during morcellation may lead to decrease in morcellation time and increased ME during HoLEP. As the scope of HoLEP usage increases, the need for efficient operative techniques becomes increasingly imperative. This study helps expand the possibilities of one aspect of HoLEP and refine mechanical morcellation techniques. Future studies will serve to evaluate this finding across a larger number of institutions and evaluate ways to increase ME in large prostate cohorts (i.e., >150 g).

COMPETING INTERESTS: Dr. Slade is a consultant for Cook Medical. Dr. Rivera is a consultant for Boston Scientific and Cook Medical. The remaining authors do not report any competing personal or financial interests related to this work.

This paper has been peer reviewed.

### REFERENCES

1. Agarwal DK, Large T, Stoughton CL, et al. Real-world experience of holmium laser enucleation of the prostate with patients on anticoagulation therapy. *J Endourol* 2021;35:1036-41. <https://doi.org/10.1089/end.2020.0886>
2. Sun F, Yao H, Bao X, et al. The efficacy and safety of HoLEP for benign prostatic hyperplasia with large volume: A systematic review and meta-analysis. *A J Mens Health* 2022;16:1557988322113203. <https://doi.org/10.1177/1557988322113203>
3. Wymer KM, Narang G, Slade A, et al. Evaluation of the cost-effectiveness of surgical treatment options for benign prostatic hyperplasia. *Urology* 2023;171:96-102. <https://doi.org/10.1016/j.urol.2022.09.026>
4. Cynk M. Holmium laser enucleation of the prostate: a review of the clinical trial evidence. *Ther Adv Urol* 2014;6:62-73. <https://doi.org/10.1177/1756287213511509>
5. Jhanwar A, Sinha RJ, Bansal A, et al. Outcomes of transurethral resection and holmium laser enucleation in more than 60 g of prostate: A prospective randomized study. *Urol Ann* 2017;9:45. <https://doi.org/10.4103/0974-7796.198904>
6. Childers CP, Maggard-Gibbons M. Understanding costs of care in the operating room. *JAMA surg* 2018;153:e176233. <https://doi.org/10.1001/jamasurg.2017.6233>
7. Maskal S, Jain R, Fedrigon III D, et al. The cost of operating room delays in an endourology center. *Can Urol Assoc J* 2020;14:E304. <https://doi.org/10.5489/auaj.6099>
8. Kavousi NL, Nimmagadda N, Robles J, et al. MOSES technology for holmium laser enucleation of the prostate: A prospective double-blind randomized controlled trial. *Urology* 2021;206:104-8. <https://doi.org/10.1097/JU.0000000000001693>

9. Tuccio A, Grosso AA, Sessa F, et al. *En-Bloc* holmium laser enucleation of the prostate with early apical release: Are we ready for a new paradigm? *J Endourol* 2021;35:1675-83. <https://doi.org/10.1089/end.2020.1189>
10. Pirolo GM, Castellani D, Maggi M, et al. Does power setting impact surgical outcomes of holmium laser enucleation of the prostate? A systematic review and meta-analysis. *Cent Eur J Urol* 2022;75:153.
11. Kuo RL, Paterson RF, Kim SC, et al. Holmium laser enucleation of the prostate (HoLEP): A technical update. *World J Surg Oncol* 2003;1:1-9. <https://doi.org/10.1186/1477-7819-1-6>
12. Lee MS, Assmus M, Cooley LF, Li E, Large T, Krambeck A. Ex vivo comparison of efficiency, safety, and surgeon satisfaction in four commercial morcellators. *J Endourol* 2022;36:514-21. <https://doi.org/10.1089/end.2021.0573>
13. McAdams S, Nunez-Nateras R, Martin CJ, et al. Morcellation efficiency in holmium laser enucleation of the prostate: Oscillating morcellator outperforms reciprocating morcellator with no apparent learning curve. *Urology* 2017;106:173-7. <https://doi.org/10.1016/j.urol.2017.05.018>
14. Ibrahim A, Elhilali MM, Elkoushy MA, et al. DrillCut™ vs. VersaCut™ prostate tissue morcellation devices after holmium laser enucleation: A prospective, randomized controlled trial. *Can Urol Assoc J* 2019;13:266. <https://doi.org/10.5489/auaj.5626>
15. Dowd K, ElMansy H, Sharour W, et al. Wolf Piranha vs Storz prostate morcellation devices: A retrospective multi-institutional study. *J Endourol* 2021;35:1671-4. <https://doi.org/10.1089/end.2020.0541>
16. Ishikawa RY, Shitara T, Wakatabe Y, et al. Relationship between morcellation efficiency and enucleated tissue weight in holmium laser enucleation of the prostate (HoLEP) for patients with benign prostatic hyperplasia. *Nihon Hinyokika Gakkai zasshi. Jpn J Urol* 2011;102:675-8. <https://doi.org/10.5980/jpnjuro.102.675>
17. Sie M, Saussine C, Munier P, et al. Analysing the learning curve of prostate enucleation with the Holmium laser: A retrospective, single-center experience. *Prog Urol* 2023;33:79-87. <https://doi.org/10.1016/j.purol.2022.06.002>
18. Assmus MA, Large T, Krambeck A. Holmium laser enucleation of the prostate efficiency by prostate gland size: Is there a sweet spot? *Urology* 2021;1:202-8. <https://doi.org/10.3390/uro1040022>
19. Tay LJ, Kulkarni M, Oluwale-Ojo A, et al. HoLEPs: A comparative study of men with massive prostate volumes ≥150 mL and <150 mL. *Urology* 2022;164:197-203. <https://doi.org/10.1016/j.urol.2021.12.038>
20. Mann MF, El Tayeb M, Bhojani N, et al. Predictors of enucleation and morcellation time during holmium laser enucleation of the prostate. *Urology* 2015;86:338-42. <https://doi.org/10.1016/j.urol.2015.04.028>
21. Anil H, Güzel A, Yıldız A, et al. Predictive factors affecting morcellation efficiency in holmium laser enucleation of the prostate. *Investig Clin Urol* 2023;64. <https://doi.org/10.4111/icu.20220361>
22. Thai KH, Smith JC, Stutz J, et al. Urethral complications while using 26F vs 28F resectoscope sheaths in holmium laser enucleation of the prostate: A retrospective observational study. *J Endourol* 2021;35:165-70. <https://doi.org/10.1089/end.2020.0350>
23. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): Long-term results, reoperation rate, and possible impact of the learning curve. *Eur Urol* 2007;52:1465-72. <https://doi.org/10.1016/j.eururo.2007.04.074>
24. Stutz J, Kleingueterl C, El Tayeb M. Re: "Management of suspected bladder injury and capsular perforation after holmium laser enucleation of the prostate" by Lwin et al (*J Endourol Case Rep* 2018;4:87-90). *J Endourol Case Rep* 2018;4:147-8. <https://doi.org/10.1089/cren.2018.0074>
25. Lwin A, Hynes K, Tzou D, et al. Management of suspected bladder injury and capsular perforation after holmium laser enucleation of the prostate. *J Endourol Case Rep* 2018;4:87-90. <https://doi.org/10.1089/cren.2018.0021>
26. Kuo RL, Paterson RF, Kim SC, et al. Holmium laser enucleation of the prostate (HoLEP): A technical update. *World J Surg Oncol* 2003;1:1-9. <https://doi.org/10.1186/1477-7819-1-6>
27. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. *Urology* 1998;51:19-22. [https://doi.org/10.1016/S0090-4295\(98\)00051-X](https://doi.org/10.1016/S0090-4295(98)00051-X)
28. Wasserman NF, Spilseth B, Golzarian J, et al. Use of MRI for lobar classification of benign prostatic hyperplasia: Potential phenotypic biomarkers for research on treatment strategies. *Am J Roentgenol* 2015;205:564. <https://doi.org/10.2214/AJR.14.13602>

CORRESPONDENCE: Dr. Cameron McClaine, Department of Urology, Indiana University School of Medicine, Indianapolis, IN, United States; [camamccl@iu.edu](mailto:camamccl@iu.edu)